1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sun Pharma Advanced Research Co. Ltd.

Sun Pharma Advanced Research Co. Ltd.

173.09
INR
-6.18
(-3.45%)
48.84EPS
4.81P/E
76.18BMarket Cap
Sun Pharma Advanced Research Co. Ltd.
NSE:SPARC
(National Stock Exchange of India)

Recent

price

173.09

P/E

ratio

4.81

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
2.75
1.37
3.98
7.01
6.58
6.81
7.35
3.15
7.15
2.93
9.65
5.22
8.39
2.33
2.21
1.21
58.86
Revenue per Share
-0.4
-3.41
-1.03
1.27
-1.67
-2.96
-4.84
-7.94
-5.69
-11.92
-5.77
-7.73
-7.82
-11.93
-10.55
47.86
48.84
Basic EPS, GAAP
-0.12
-3.49
-4.51
1.39
-2.08
-2.39
-5.55
-8.68
-7.23
-10.11
-6.03
-9.16
-2.97
-14.04
-11.42
-8.09
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.27
-3.14
4.55
5.84
4.19
1.27
6.41
7.36
11.3
-0.71
-6.42
1.15
15.8
3.88
-6.69
41.26
- -
Book Value per Share
0.27
-3.14
4.55
5.84
4.19
1.27
6.41
7.35
11.28
-1.83
-6.45
0.3
15.02
2.56
-8.34
39.06
- -
Tangible Book Value per Share
212
212
219
238
237
237
246
248
256
262
262
263
285
325
325
325
324
Basic Weighted Avg Shares
583
290
873
1,670
1,557
1,613
1,810
783
1,829
768
2,530
1,372
2,388
755
718
391
19,095
Sales/Revenue/Turnover
-16.48
-252.2
-22.55
18.09
-26.92
-43.49
-72.24
-320.44
-83.18
-410.02
-57.68
-142.86
-93.66
-544.71
-465.49
4,084.29
84.17
Operating Margin (%)
30
32
34
36
72
76
82
82
76
95
109
102
118
125
124
102
97
Depreciation Expense
-85
-722
-225
303
-395
-700
-1,190
-1,970
-1,454
-3,124
-1,511
-2,034
-2,226
-3,872
-3,425
15,532
15,843
Net Income, GAAP
- -
- -
- -
11.65
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-14.57
-249.28
-25.77
18.15
-25.38
-43.4
-65.76
-251.73
-79.53
-406.7
-59.75
-148.19
-93.22
-512.56
-477.26
3,967.49
82.97
Profit Margin (%)
-522
-1,268
448
713
258
-588
503
591
1,623
-1,682
-1,702
-1,003
2,760
43
-3,480
11,083
- -
Working Capital
63
57
44
38
33
27
22
16
11
64
1,167
24
126
107
1,069
17
- -
LT Debt
56
-666
1,084
1,393
998
300
1,582
1,847
2,962
-186
-1,683
312
5,128
1,258
-2,169
13,388
- -
Total Equity
- -
- -
- -
15.99
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
21.13
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-86.09
- -
- -
24.48
-33.06
-107.81
-126.5
-114.91
-60.48
- -
- -
- -
-81.83
-121.28
- -
- -
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
5,561
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
17
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
325
325
325
Market Capitalization
43,632
37,284
76,181

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
18,624
- -
Cash, Cash Equivalents & STI
- -
13
- -
Accounts Receivable, Net
- -
83
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
7,541
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
5,561
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
155.85%
71.7%
-717.12%
Free Cash Flow
56.71%
75.82%
-29.15%
Net Income, GAAP
-27.45%
-89.41%
-553.48%
Sales/Revenue/Turnover
16.99%
-18.11%
-45.45%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
168
129
149
272
718
2026
96
79
85
18,532
391
2027
399
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-2.96
-3.31
-2.45
-1.84
-10.55
2026
-1.6
-2.34
-2.48
54.27
47.86
2027
-0.64
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sun Pharma Advanced Research Company Limited (SPARC.NS) is a clinical-stage biopharmaceutical company focused on the research, development, and innovation of novel therapeutics and drug delivery systems to enhance patient care globally; core products and pipeline candidates target oncology through initiatives like the antibody-drug conjugate SBO-154 for solid tumors and BCR-ABL1 tyrosine kinase inhibitors; neurology, including assets for Parkinson's disease in Phase II trials and neurodegeneration programs pursuing novel pathways; immunology; ophthalmology to improve patient compliance; and dermatology with differentiated therapies for medical dermatology; the company also advances novel chemical entities (NCEs) and novel drug delivery systems (NDDS). SPARC operates primarily from its headquarters in Mumbai, India, with additional facilities in Pune, Maharashtra; founded in 2006 through a demerger from Sun Pharmaceutical Industries Limited, it maintains a single reportable segment in pharmaceutical research and development across India and international markets, employing approximately 316 people. Recent developments include the submission of an Investigational New Drug (IND) application to the US FDA in March 2025 for SBO-154 ahead of its Phase I clinical trial in solid tumors; incorporation of a new wholly owned subsidiary, Genokine Biotech Limited, in July 2025 to support strategic expansion, though it remains pre-commercial; and increased capital expenditures to ₹2,314 lakhs alongside intangible assets under development reaching ₹7,121 lakhs as of September 2025, reflecting heightened R&D investments amid ongoing clinical progress despite reported operational losses.